BetterLife Pharma Appoints Former Cybin CEO Doug Drysdale as Corporate Advisor to Advance Non-Psychiatric Applications of BETR-001

BetterLife Pharma Inc. has appointed Doug Drysdale, former CEO of Cybin Inc., as Corporate Advisor to advance the company's product BETR-001's non-psychiatric indications with focus on cluster headache and migraine. Drysdale brings extensive pharmaceutical leadership experience, having led Cybin from molecule inception to Phase 3 trials in just three years, demonstrating his capability to accelerate drug development timelines significantly. His appointment signals BetterLife's strategic push to leverage his expertise in navigating complex regulatory pathways and building successful pharmaceutical companies.

Dr. Ahmad Doroudian, CEO of BetterLife, emphasized Drysdale's value, stating he is a globally recognized leader and strategist with over 35 years experience delivering multiple successful transactions in various different markets and indications. The company anticipates Drysdale's guidance will be instrumental in developing BETR-001 for treatment of cluster headache, migraine and neuropathic pain. BETR-001 represents a significant advancement as BetterLife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD that previous research has shown to be safe and tolerable in humans while demonstrating meaningful reduction in cluster headache frequency in clinical studies.

Drysdale's pharmaceutical career includes transformative leadership roles across multiple companies. As Founding CEO of Alvogen, he grew the company from inception to $500 million in revenues across 35 countries in 5.5 years, establishing research and development in New Jersey, a CRO in India, and a 50-product U.S. pipeline. His earlier work at Norwich Pharmaceuticals involved enhancing manufacturing and R&D capabilities, while his tenure as Chairman and CEO of Pernix Therapeutics saw him recapitalize the company with $65 million, rebuild leadership, and grow enterprise value from $80 million to $800 million. More recently, as CEO of Tedor Pharma, he achieved 60% revenue growth in 2019, earning the company a spot on the 2020 Inc 5000 list.

BetterLife's BETR-001 candidate holds particular promise because it is a non-hallucinogenic and non-controlled LSD derivative in development, making it unique in that it is unregulated and therefore can be self-administered. The company's synthesis patent for BETR-001 eliminates regulatory hurdles, while its pending patent for composition and method of use covers treatment of various neurological disorders until around 2042. This intellectual property protection, combined with Drysdale's experience in commercializing pharmaceutical products, positions BetterLife to potentially bring innovative treatments to patients suffering from debilitating neurological conditions. For additional information about the company's developments, visit New Media Wire where the original announcement was published.